Cancer nanotherapeutics in clinical trials

Area of Science:

• Oncology
• Nanotechnology
• Drug Development

Background:

• All drugs require Food and Drug Administration (FDA) approval for legal sale in the U.S.
• Understanding the FDA approval process and clinical trial requirements is crucial for drug development.
• Cancer nanotherapeutics and in vivo diagnostics represent a growing field in oncology.

Purpose of the Study:

• To introduce the FDA drug approval process.
• To describe the clinical trials necessary for drug approval.
• To review current cancer nanotherapeutics and in vivo diagnostics in clinical trials or approved by the FDA.

Main Methods:

• Literature review of the FDA drug approval pathway.
• Analysis of clinical trial phases and requirements.
• Categorization and description of nanotechnologies based on delivery vehicles.

Main Results:

• The FDA approval process involves rigorous clinical trials.
• Various nanotechnologies, including liposomes, polymer micelles, and albumin-bound agents, are utilized in cancer therapy.
• Several nanotherapeutics and in vivo diagnostics have either completed clinical trials or received FDA approval.

Conclusions:

• The FDA approval process is a critical gatekeeper for novel therapeutics.
• Nanotechnology offers promising advancements in cancer treatment and diagnostics.
• Delivery vehicles like liposomes and polymer-based systems are key components of approved and investigational nanomedicines.